Pharmacy and Poisons Board

Pharmacy and Poisons Board

Ensuring Safety, Quality and Efficacy of Medicines

Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 1 of 39, showing 5 Applications out of 192 total, starting on record 1, ending on 5

# Protocol No Study Title Investigator(s) & Site(s) Application Status

1.

ECCT/08/06/01  
    Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples   
Principal Investigator(s)
1. Elizabeth Anne Bukusi
Site(s) in Kenya
1. Kisumu site (Kisumu county)
 
Trial Status Analysing
Protocol Date 12-10-2007
View

2.

ECCT/08/08/02  
    Parallel Comparison of Tenofovir and Emtricitabine/tenofovir Pre-Exposure Prophylaxis to Prevent HIV-1 Acquisition within HIV-1 Discordant Couples   
Principal Investigator(s)
1. Edwin Onyango Were
Site(s) in Kenya
1. Eldoret Site (Uasin Gishu county)
2. Kisumu Site (Kisumu county)
3. Thika Site (Kiambu county)
4. Nairobi Site (Nairobi City county)
 
Trial Status (not set!)
Protocol Date 12-10-2007
View

3.

ECCT/08/08/03   Partners PrEP Study
    Parallel Comparison of Tenofovir and Emtricitabine/Tenofovir Pre-exposure Prophylaxis to Prevent HIV-1 Acquisition  within HIV-1 Discordant Couples.    
Principal Investigator(s)
1. Prof. Connie Celum
Site(s) in Kenya
1. Kenya- Eldoret (Uasin Gishu county)
2. Kenya – Nairobi (Nairobi City county)
3. Kenya – Kisumu (Kisumu county)
4. Kenya – Thika (Uasin Gishu county)
 
Trial Status Analysing
Protocol Date 12-10-2007
View

4.

ECCT/08/20/01   Partners PrEP Study
    Parallel comparison of Tenofovir and Emtricitabine/Tenofovir pre exposure prophylaxis to prevent HIV-1 acquisition within HIV-1 discordant couples   
Principal Investigator(s)
1. James Njogu Kiarie
2. CAREY FARQUHAR,
3. Grace John Stewart
Site(s) in Kenya
1. Nairobi (Nairobi City county)
2. Thika (Kiambu county)
3. Eldoret (Uasin Gishu county)
4. Kisumu (Kisumu county)
 
Trial Status Analysing
Protocol Date 12-10-2007
View

5.

ECCT/08/27/12   MAL 55: A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection.
    Protocol No. 110021 - MAL 55 STUDY   A phase III, double blind (observer-blind), randomised, controlled multicenter study to evaluate, in infants and children, the efficacy of the RTS,S/AS01E candidate vaccine against malaria disease caused by P. falciparum infection, across diverse malaria transmission settings in Africa”   
Principal Investigator(s)
1. Dr. Mary Hamel
2. Dr. Patricia Njuguna
3. Dr. Walter Otieno
Site(s) in Kenya
1. KEMRI - CDC RESEARCH INSTITUTION CENTRE, KISUMU (Kisumu county)
2. KEMRI-WELLCOME TRUST RESEARCH CENTER, KILIFI SITE (Kilifi county)
3. KEMRI-WALTERREED, RESEARCH CENTRE, KOMBEWA SITE (Kisumu county)
 
Trial Status completed
Protocol Date 08-08-2012
View